FIELD: medicine.
SUBSTANCE: invention concerns medicine, particularly oncology, and can be applied in treatment of tumours expressing G250 antigen. Manufacturing of medicine for supporting therapy in case of non-metastatic disease after dissection of primary tumour expressing G250 antigen involves G-250-specific antibody and/or antibody fragment.
EFFECT: reduced risk of tumour recurrence due to cell cytotoxicity dependent on given antibody.
18 cl, 4 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| IMPROVED ADJUVANT THERAPY OF G250 EXPRESSING TUMOURS | 2005 |
|
RU2519340C2 |
| TREATMENT OF MALIGNANT NEOPLASMS BASED ON CAIX STRATIFICATION | 2014 |
|
RU2663694C2 |
| SELECTIVE DETECTION OF BONE METASTASES IN CLEAR CELL RENAL CELL ADENOCARCINOMA | 2010 |
|
RU2536290C2 |
| METHOD FOR EARLY DIAGNOSIS OF RENAL CELL CARCINOMA BY THE PRESENCE OF ANTIBODIES TO THE VISUAL ARRESTIN | 2018 |
|
RU2707884C1 |
| METHOD FOR EARLY DIAGNOSIS OF RENAL CELL CARCINOMA BY OBSERVING PRESENCE OF VISUAL ARRESTIN IN BLOOD SERUM | 2020 |
|
RU2741245C1 |
| METHOD OF DIAGNOSING RENAL CELL CARCINOMA BY PRESENCE OF ARRESTIN AND RECOVERIN VISUAL PROTEINS IN URINE | 2022 |
|
RU2805811C1 |
| METHOD FOR PREDICTION OF ONCOLOGICAL SURVIVAL RATE IN PATIENTS WITH NONMETASTATIC RENAL CELL CARCINOMA AFTER MALIGNANT NEPHRECTOMY OR PARTIAL NEPHRECTOMY | 2010 |
|
RU2438127C1 |
| METHOD FOR BLADDER CANCER COURSE PREDICTION | 2017 |
|
RU2641170C1 |
| METHOD FOR PREDICTING TARGETED THERAPY EFFECTIVENESS IN PATIENTS WITH LIGHT CELL KIDNEY CANCER | 2020 |
|
RU2750026C1 |
| ALK1 ANTAGONISTS AND THEIR APPLICATION IN THE TREATMENT OF KIDNEY-CELLULAR CARCINOMA | 2013 |
|
RU2633638C2 |
